Compare EPR & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPR | CRNX |
|---|---|---|
| Founded | 1997 | 2008 |
| Country | United States | United States |
| Employees | 54 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 3.9B |
| IPO Year | N/A | 2018 |
| Metric | EPR | CRNX |
|---|---|---|
| Price | $63.53 | $83.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $58.94 | ★ $76.75 |
| AVG Volume (30 Days) | 531.5K | ★ 6.8M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.28% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,039,000.00 |
| Revenue This Year | $2.66 | $720.10 |
| Revenue Next Year | $8.60 | $184.67 |
| P/E Ratio | $25.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $48.11 | $25.83 |
| 52 Week High | $63.30 | $84.00 |
| Indicator | EPR | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 73.33 | 92.07 |
| Support Level | $57.44 | $33.50 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.00 | 0.18 |
| MACD | 0.24 | -0.10 |
| Stochastic Oscillator | 99.52 | 53.51 |
EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.